Home » Market News » DirectorsTalk Highlights » Addressing gaps in systemic lupus erythematosus management
Immupharma Plc

Addressing gaps in systemic lupus erythematosus management

Lupus is on the rise, yet awareness of the disease remains relatively low, however, efforts are underway to tackle existing gaps in managing the condition

Lupus is an autoimmune disease, which basically means that the immune system produces antibodies that attack the body’s own tissues, causing inflammation. The two main types of lupus are discoid lupus and systemic lupus erythematosus (SLE) – the focus of this article will be on the latter.

By way of introduction, we know that systemic lupus erythematosus (SLE) is the most common form of lupus, affecting approximately 70% of the estimated 5 million people with lupus worldwide.

Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.